These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 30790067)

  • 1. Support Groups in Scleroderma.
    Rice DB; Thombs BD
    Curr Rheumatol Rep; 2019 Feb; 21(4):9. PubMed ID: 30790067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protocol for a partially nested randomized controlled trial to evaluate the effectiveness of the Scleroderma Patient-centered Intervention Network Support Group Leader EDucation (SPIN-SSLED) Program.
    Thombs BD; Aguila K; Dyas L; Carrier ME; Fedoruk C; Horwood L; Cañedo-Ayala M; Sauvé M; Kwakkenbos L; Malcarne VL; El-Baalbaki G; Peláez S; Connolly K; Hudson M; Platt RW;
    Trials; 2019 Dec; 20(1):717. PubMed ID: 31831073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of training and support programs for leaders of illness-based support groups: commentary and updated evidence.
    Turner KA; Rice DB; Carboni-Jiménez A; Boruff J; Thombs BD
    Syst Rev; 2019 Mar; 8(1):67. PubMed ID: 30836989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scleroderma Patient-centered Intervention Network-Scleroderma Support group Leader EDucation (SPIN-SSLED) program: non-randomised feasibility trial.
    Thombs BD; Dyas L; Pépin M; Aguila K; Carrier ME; Tao L; Harb S; Malcarne VL; El-Baalbaki G; Peláez S; Sauve M; Hudson M; Platt RW;
    BMJ Open; 2019 Nov; 9(11):e029935. PubMed ID: 31719073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reasons for non-participation in scleroderma support groups.
    Delisle VC; Gumuchian ST; Pelaez S; Malcarne VL; El-Baalbaki G; Körner A; Hudson M; Baron M; Thombs BD;
    Clin Exp Rheumatol; 2016; 34 Suppl 100(5):56-62. PubMed ID: 26950221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of a support group leader education program jointly developed by health professionals and patients on peer leader self-efficacy among leaders of scleroderma support groups: a two-arm parallel partially nested randomised controlled trial.
    Thombs BD; Levis B; Carrier ME; Dyas L; Nordlund J; Tao L; Aguila K; Bourgeault A; Konrad V; Sauvé M; Connolly K; Henry RS; Østbø N; Levis AW; Kwakkenbos L; Malcarne VL; El-Baalbaki G; Hudson M; Wurz A; Culos-Reed SN; Platt RW; Benedetti A;
    Orphanet J Rare Dis; 2022 Oct; 17(1):396. PubMed ID: 36307891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Training and support needs of scleroderma support group facilitators: the North American Scleroderma Support Group Facilitators Survey.
    Delisle VC; Gumuchian ST; El-Baalbaki G; Körner A; Malcarne VL; Peláez S; Carrier ME; Pépin M; Thombs BD;
    Disabil Rehabil; 2019 Oct; 41(20):2477-2482. PubMed ID: 29696997
    [No Abstract]   [Full Text] [Related]  

  • 8. Reasons for Not Participating in Scleroderma Patient Support Groups: A Cross-Sectional Study.
    Gumuchian ST; Delisle VC; Peláez S; Malcarne VL; El-Baalbaki G; Kwakkenbos L; Jewett LR; Carrier ME; Pépin M; Thombs BD;
    Arthritis Care Res (Hoboken); 2018 Feb; 70(2):275-283. PubMed ID: 28217869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reasons for not participating in scleroderma patient support groups: a comparison of results from the North American and European scleroderma support group surveys.
    Kwakkenbos L; Carboni-Jiménez A; Carrier ME; Pépin M; Peláez S; Malcarne VL; El-Baalbaki G; Thombs BD;
    Disabil Rehabil; 2021 May; 43(9):1279-1286. PubMed ID: 31522575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reasons for attending support groups and organizational preferences: the European scleroderma support group members survey.
    Gumuchian ST; Delisle VC; Kwakkenbos L; Pépin M; Carrier ME; Malcarne VL; Peláez S; El-Baalbaki G; Thombs BD;
    Disabil Rehabil; 2019 Apr; 41(8):974-982. PubMed ID: 29254393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and preliminary validation of the Scleroderma Support Group Leader Self-efficacy Scale.
    Pal NE; Gumuchian ST; Delisle VC; Pépin M; Malcarne VL; Carrier ME; Kwakkenbos L; Peláez S; El-Baalbaki G; Thombs BD;
    J Scleroderma Relat Disord; 2018 Feb; 3(1):106-111. PubMed ID: 35382120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Scleroderma Patient-Centered Intervention Network Self-Management Program: Protocol for a Randomized Feasibility Trial.
    Carrier ME; Kwakkenbos L; Nielson WR; Fedoruk C; Nielsen K; Milette K; Pope J; Frech T; Gholizadeh S; Hummers L; Johnson SR; Piotrowski P; Jewett L; Gordon J; Chung L; Bilsker D; Turner KA; Cumin J; Welling J; Fortune C; Leite C; Gottesman K; Sauve M; Rodríguez-Reyna TS; Hudson M; Larche M; van Breda W; Suarez-Almazor ME; Bartlett SJ; Malcarne VL; Mayes MD; Boutron I; Mouthon L; Wigley F; Thombs BD;
    JMIR Res Protoc; 2020 Apr; 9(4):e16799. PubMed ID: 32329747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exercise habits and factors associated with exercise in systemic sclerosis: a Scleroderma Patient-centered Intervention Network (SPIN) cohort study.
    Azar M; Rice DB; Kwakkenbos L; Carrier ME; Shrier I; Bartlett SJ; Hudson M; Mouthon L; Poiraudeau S; van den Ende CHM; Johnson SR; Rodriguez Reyna TS; Schouffoer AA; Welling J; Thombs BD;
    Disabil Rehabil; 2018 Aug; 40(17):1997-2003. PubMed ID: 28478701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized feasibility trial of the Scleroderma Patient-centered Intervention Network hand exercise program (SPIN-HAND): Study protocol.
    Carrier ME; Kwakkenbos L; Boutron I; Welling J; Sauve M; van den Ende C; Schouffoer AA; Hudson M; Thombs BD; Mouthon L;
    J Scleroderma Relat Disord; 2018 Feb; 3(1):91-97. PubMed ID: 35382119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A qualitative interview study exploring the psychological health impacts of the SPIN-CHAT program among people with systemic sclerosis at the onset of COVID-19: perceptions of trial participants and research team members.
    Wurz A; Duchek D; Ellis K; Bansal M; Carrier ME; Tao L; Dyas L; Kwakkenbos L; Levis B; El-Baalbaki G; Rice DB; Wu Y; Henry RS; Bustamante L; Harb S; Hebblethwaite S; Patten SB; Bartlett SJ; Varga J; Mouthon L; Markham S; Thombs BD; Culos-Reed SN; ; ;
    Disabil Rehabil; 2024 Feb; 46(3):533-545. PubMed ID: 36708187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Support and training needs of cancer support group leaders: a review.
    Price M; Butow P; Kirsten L
    Psychooncology; 2006 Aug; 15(8):651-63. PubMed ID: 16294369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of the nominal group technique to identify stakeholder priorities and inform survey development: an example with informal caregivers of people with scleroderma.
    Rice DB; Cañedo-Ayala M; Turner KA; Gumuchian ST; Malcarne VL; Hagedoorn M; Thombs BD;
    BMJ Open; 2018 Mar; 8(3):e019726. PubMed ID: 29500214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The evaluation of a home-based program for hands in patients with systemic sclerosis.
    Landim SF; Bertolo MB; Marcatto de Abreu MF; Del Rio AP; Mazon CC; Marques-Neto JF; Poole JL; de Paiva Magalhães E
    J Hand Ther; 2019; 32(3):313-321. PubMed ID: 29198478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges and strategies for coping with scleroderma: implications for a scleroderma-specific self-management program.
    Milette K; Thombs BD; Maiorino K; Nielson WR; Körner A; Peláez S
    Disabil Rehabil; 2019 Oct; 41(21):2506-2515. PubMed ID: 29741963
    [No Abstract]   [Full Text] [Related]  

  • 20. Validation of the Self-Efficacy for Managing Chronic Disease Scale: A Scleroderma Patient-Centered Intervention Network Cohort Study.
    Riehm KE; Kwakkenbos L; Carrier ME; Bartlett SJ; Malcarne VL; Mouthon L; Nielson WR; Poiraudeau S; Nielsen K; Baron M; Frech T; Hudson M; Pope J; Sauve M; Suarez-Almazor ME; Wigley FM; Thombs BD;
    Arthritis Care Res (Hoboken); 2016 Aug; 68(8):1195-200. PubMed ID: 26619042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.